NO PODCAST ONCONEWS, os médicos Silvio Bromberg e Daniel Gimenes comentam alguns dos estudos que foram destaque na programação científica do San Antonio Breast Cancer Symposium 2023 (SABCS 2023). Entre os trabalhos selecionados, estudo de coorte internacional que avalia a gravidez após o câncer de mama em mulheres jovens com variantes patogênicas germinativas do BRCA; e resultados de cinco anos do ensaio IDEA, que investiga o tratamento com terapia endócrina e omissão da radioterapia após cirurgia conservadora da mama em pacientes na pós-menopausa com câncer de mama em estágio I selecionadas por teste genômico. Confira.
Referências:
Oncologia Clínica
- GS02-13: Pregnancy after Breast Cancer in Young Women with Germline BRCA Pathogenic Variants: Results from an International Cohort Study
- GS03-03 Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial
- GS01-01 - Biomarker results in high-risk estrogen receptor positive, human epidermal growth factor receptor 2 negative primary breast cancer following neoadjuvant chemotherapy ± nivolumab: an exploratory analysis of CheckMate 7FL
- Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple-Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study
- Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2− Breast Cancer: KEYNOTE-756
Cirurgia
- GS02-08 Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically selected favorable Stage I breast câncer
- PS01-06 The relationship between margin status of < 2mm and local recurrence in DCIS patients
- GS02-02 Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study
- GS02-04 Surgical Treatment of Women with Breast Cancer and a BRCA1 Mutation: An International Analysis of the Impact of Bilateral Mastectomy on Survival
- GS02-06 Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial.
- GS02-07 Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304
--
